Patil Vaishali M, Masand Neeraj, Gupta Satya P, Blagg Brian S J
Department of Pharmaceutical Chemistry, KIET School of Pharmacy, KIET Group of Institutions, Delhi-NCR, Ghaziabad, Uttar Pradesh, India.
Department of Pharmacy, Lala Lajpat Rai Memorial Medical College, Meerut, Uttar Pradesh, India.
Curr Top Med Chem. 2021;21(25):2272-2291. doi: 10.2174/1568026621666211011095858.
Heat shock protein 90 (HSP90) is a multichaperone complex that mediates the maturation and stability of a variety of oncogenic signaling proteins. HSP90 has emerged as a promising target for the development of anticancer agents. Heterocyclic chemical moieties with HSP90 inhibitory activity were studied continuously during the last decades, and resulting data were applied by medicinal chemists to design and develop new drugs. Their structure-activity relationship (SAR) studies and QSAR models have been derived to assist the current drug development process. The QSAR models are obtained via multiple linear regression (MLR) and non-linear approaches. Interpretation of the reported model highlights the core template required to design novel, potent HSP90 inhibitors to be used as anticancer agents.
热休克蛋白90（HSP90）是一种多分子伴侣复合物，可介导多种致癌信号蛋白的成熟和稳定性。HSP90已成为开发抗癌药物的一个有前景的靶点。在过去几十年中，人们不断研究具有HSP90抑制活性的杂环化学部分，药物化学家利用所得数据来设计和开发新药。已经得出了它们的构效关系（SAR）研究和定量构效关系（QSAR）模型，以辅助当前的药物开发过程。QSAR模型是通过多元线性回归（MLR）和非线性方法获得的。对所报道模型的解释突出了设计新型、强效HSP90抑制剂用作抗癌药物所需的核心模板。
